Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;75(2):115-20.
doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3.

Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

David van Duin  1 , Keith S Kaye, Elizabeth A Neuner, Robert A Bonomo
Affiliations
Review

Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes

David van Duin et al. Diagn Microbiol Infect Dis. 2013 Feb.

Abstract

The emergence of carbapenem resistance in Enterobacteriaceae is an important threat to global health. Reported outcomes of infections with carbapenem-resistant Enterobacteriaceae (CRE) are poor. Very few options remain for the treatment of these virulent organisms. Antibiotics which are currently in use to treat CRE infections include aminoglycosides, polymyxins, tigecycline, fosfomycin, and temocillin. In addition, the role of combination therapy, including carbapenem containing regimens, remains to be defined. There are several important concerns regarding all of these treatment options such as limited efficacy, increasing reports of resistance, and specific toxicities. Data from retrospective studies favor combination therapy over single-agent therapy for the treatment of CRE bloodstream infections. In summary, new antibiotics are greatly needed, as is additional prospective research.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Chemical structures of antimicrobials which may have in vitro activity against carbapenem-resistant Enterobacteriaceae.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Alexander BT, Marschall J, et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther. 2012;34:1314–1323. - PMC - PubMed
    1. Ben-David D, Kordevani R, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60. - PubMed
    1. Boelaert J, Daneels R, et al. The pharmacokinetics of temocillin in patients with normal and impaired renal function. J Antimicrob Chemother. 1983;11:349–356. - PubMed
    1. Borer A, Saidel-Odes L, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol. 2009;30:972–976. - PubMed
    1. Borsa F, Leroy A, et al. Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults. Antimicrob Agents Chemother. 1988;32:938–941. - PMC - PubMed

Publication types

MeSH terms